Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research LimitedfiledCriticalCantab Pharmaceuticals Research Limited
Publication of TR199900160T2publicationCriticalpatent/TR199900160T2/en
Papilomvirüsten türemis antijenler içeren füsyon polipeptidleri ve bunlarin toplamlari, bunlarin bilesimleri ve ör. yardimci nitelik tasiyan maddelerle birlikte HPV'ye özel bagisiklik tepkileri olusturmak için bagisiklik kazandirici ve asi amaçli olarak bunlarin kullanimi. Polipeptidler, solüsyon ya da bir dagilimda bir sterilizasyon filtresinden ve sekilsiz olarak geçebilmek üzere toplamlar halinde saflastirilabilirler. Böyle bir polipeptid örnegi olarak insan papilomvirüs proteinleri olan L2 ve E7'nin füsyon proteini verilebilir.Fusion polypeptides containing antigens derived from papilomvirus and their totals, combinations thereof and e.g. Use of immune and rebellious purposes to generate immune responses specific to HPV with adjuvant substances. Polypeptides can be purified in total in a solution or distribution to pass through a sterilization filter and without form. As an example of such a polypeptide, the fusion protein of L2 and E7, human papilomvirus proteins, can be given.
TR1999/00160T1996-07-291996-07-29
Useful polypeptides as immunotherapeutic active ingredients.
TR199900160T2
(en)